Recent advances in high-throughput gene sequencing and other omics biotechnologies have served as a springboard for the field of pharmacogenomics. Pharmacogenomics is now generally accepted as the major determinant of variable drug safety, efficacy, and cost-effectiveness. Therefore, widespread use of pharmacogenomics for patient care has become a critical requirement. There is an unprecedented urgency for aspiring and practicing clinicians to become trained on how to interpret data from pharmacogenomic testing in preparation for the future of healthcare--i.e., personalized medicine.
Applying Pharmacogenomics in Therapeutics provides timely coverage of the principles, practice, and potential of pharmacogenomics and personalized medicine. Comprised of chapters contributed by well-established pharmacologists and scientists from US and Chinese academia and industry, this authoritative text:
- Demonstrates how to apply the principles of pharmacogenomics and its biotechnologies in patient care
- Depicts the use of genetic biomarkers in drug discovery and development, laboratory medicine, and clinical services
- Describes the practice of pharmacogenomics in the treatment of cancers, cardiovascular diseases, neurologic and psychiatric disorders, and pulmonary diseases
- Discusses the merging of pharmacogenomics and alternative medicine, as well as the integration of pharmacogenomics into pharmacoeconomics
Each chapter begins with the key concepts, followed by in-depth explorations of case reports or critical evaluations of genetic variants/biomarkers, and concludes with questions for self-examination.
Xiaodong Feng, PhD, PharmD, began his biomedical research career 19 years ago in the Wound Healing Center, Stony Brook School of Medicine, Stony Brook, New York, USA. He then served for four years as assistant professor in the Department of Dermatology at the State University of New York at Stony Brook, USA. Currently, Dr. Feng is professor of Pharmacology and Oncology, and Associate Dean at California Northstate University College of Medicine, Elk Grove, USA; clinical pharmacist at Sutter Davis Hospital, California, USA; and oncology pharmacy specialist at Dignity Health Medical Foundation, Rancho Cordova, California, USA.
Hong-Guang Xie, MD, PhD, earned his degrees from Central South University Xiangya School of Medicine, Changsha, China, was promoted to lecturer, and then to associate professor of pharmacology. Subsequently, he served as co-founder and associate director of the Pharmacogenetics Research Institute, Changsha, China; postdoctoral research fellow and faculty research instructor at Vanderbilt University, Nashville, Tennessee, USA; staff research fellow at the University of California Washington Center, DC, USA; and Oak Ridge Institute for Science and Education (ORISE) fellow for the United States Food and Drug Administration (US FDA). Dr. Xie is currently full professor of pharmacology and chief of the General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, China.
